Treatment for Challenging Lesions
For the complete TAXUS VI Randomized International Complex Trial data in portable document format (PDF),
click here.
| Objective: |
Evaluate target vessel revascularization (TVR) rate for TAXUS® Express2™ Paclitaxel-Eluting MR Stent for long lesions. |
| Number of Patients: |
448, 446 patients evaluated |
| Number of Sites: |
44 |
| Lesion Type: |
de novo, 18-40 mm |
| Stent Platform: |
Express 8, 16, 24 and 32 mm lengths, 2.5, 3.0 and 3.5 mm diameters |
| Release Kinetics: |
Moderate |
| Primary Endpoint: |
9-month TVR |
| P.I. and Co-P.I.: |
K. Dawkins, M.D. and E. Grube, M.D. |
| Status: |
Enrollment complete
|
Caution: The TAXUS Express Moderate Release Paclitaxel-Eluting Stent is an investigational device and not approved for sale in the United States. The safety and efficacy of this device have not been established.
